What is the standard end‑of‑life medication bundle, including a fentanyl transdermal patch and adjunctive drugs, for an adult opioid‑tolerant hospice patient?

Standard End-of-Life Medication Bundle for Hospice Care

For an opioid-tolerant adult hospice patient, a standard end-of-life medication bundle should include: transdermal fentanyl patch (dose based on prior opioid requirements), subcutaneous morphine or hydromorphone for breakthrough pain, an antiemetic (haloperidol or prochlorperazine), a benzodiazepine (lorazepam), an anticholinergic for secretions (glycopyrrolate or atropine), and a laxative.

Core Medication Bundle Components

1. Long-Acting Opioid: Transdermal Fentanyl

Transdermal fentanyl is the preferred long-acting opioid for hospice patients who are opioid-tolerant, particularly those unable to swallow or with poor compliance 1, 2. The FDA label explicitly states fentanyl patches are only for opioid-tolerant patients taking at least 60 mg oral morphine daily (or equivalent) for one week or longer 3.

Dosing conversion for fentanyl patches:

• 60 mg oral morphine/day = 25 mcg/h patch
• 120 mg oral morphine/day = 50 mcg/h patch
• 180 mg oral morphine/day = 75 mcg/h patch
• 240 mg oral morphine/day = 100 mcg/h patch 4

Critical considerations:

• Patches take 12-24 hours to reach therapeutic levels; continue short-acting opioids during this period 4
• Duration is typically 72 hours, though some patients require 48-hour changes 4
• When converting from IV fentanyl infusion, use 1:1 ratio (mcg/h IV = mcg/h transdermal) 5
• Never use patches for unstable pain requiring frequent dose adjustments 4

2. Breakthrough Pain: Short-Acting Opioids

Subcutaneous morphine or hydromorphone is essential for breakthrough pain and dyspnea 6, 7, 8. The subcutaneous route becomes increasingly important as patients approach death, with studies showing a significant shift from oral to subcutaneous administration during hospice stay 7.

Breakthrough dosing:

• Calculate 10% of total daily opioid dose as the breakthrough dose 9
• For morphine: 2-5 mg IV/subcutaneous for opioid-tolerant patients 1, 5
• For hydromorphone: proportionally less (approximately 1:5 ratio to morphine) 1
• If requiring >4 breakthrough doses daily, increase baseline long-acting opioid 9

For dyspnea management specifically: Consider a 25% increase in baseline opioid dose 6. Nebulized fentanyl has shown promise but requires further study 6.

3. Antiemetics

Haloperidol and prochlorperazine are the most commonly prescribed antiemetics in hospice 8, 10. These address nausea from opioids, disease progression, and metabolic derangements.

Standard orders:

• Haloperidol 0.5-2 mg subcutaneous/oral every 4-6 hours PRN
• Prochlorperazine 5-10 mg oral/rectal every 6-8 hours PRN

4. Anxiolytics/Sedatives

Lorazepam is the most commonly prescribed benzodiazepine in hospice settings 8, 10. It addresses anxiety, agitation, and dyspnea when combined with opioids.

Standard orders:

• Lorazepam 0.5-2 mg sublingual/subcutaneous every 4-6 hours PRN
• Important caveat: The beneficial effect of benzodiazepines on dyspnea alone is small; they work best when dyspnea is associated with anxiety 6

5. Anticholinergics for Secretions

Glycopyrrolate, atropine, hyoscyamine, or scopolamine reduce excessive secretions (death rattle) 6, 10.

Preferred agent: Glycopyrrolate because it doesn't cross the blood-brain barrier and is less likely to cause delirium 6.

Standard orders:

• Glycopyrrolate 0.2-0.4 mg subcutaneous every 4-6 hours PRN
• Atropine 0.4 mg sublingual/subcutaneous every 4 hours PRN (alternative)
• Avoid transdermal scopolamine patches for imminently dying patients (12-hour onset too slow) 6

6. Laxatives

Laxatives are prescribed to 53% of hospice patients 11 and are essential for opioid-induced constipation management.

Standard orders:

• Senna 2 tablets oral daily
• Docusate 100 mg oral twice daily
• Polyethylene glycol 17 g oral daily PRN

7. Additional Medications Based on Symptoms

Antipsychotics for delirium:

• Haloperidol also serves this dual purpose 8, 10

Anticonvulsants:

• Used in 71% of hospice patients 11, particularly for neuropathic pain or seizure prevention

Route of Administration Hierarchy

As patients approach death, the route of administration must shift from oral to alternative routes 12, 7:

1. Oral - preferred when possible
2. Transdermal - for stable, long-acting opioid delivery
3. Sublingual/buccal - for breakthrough medications when swallowing difficult
4. Subcutaneous - increasingly important at end of life; allows bolus or continuous infusion via syringe driver 12, 7
5. Rectal - cost-effective, less invasive alternative 12

The subcutaneous route with portable infusion pumps (syringe drivers) is fundamental to end-of-life symptom control 12, 10, allowing continuous medication delivery when oral intake fails.

Common Pitfalls to Avoid

1. Never initiate fentanyl patches in opioid-naïve patients - this is an FDA contraindication and can cause fatal respiratory depression 3

2. Don't use fentanyl patches for acute or unstable pain - they require 12-24 hours to reach therapeutic levels 4

3. Avoid heat exposure to patch sites - heating pads, electric blankets, fever can accelerate absorption and cause fatal overdose 3

4. Don't forget breakthrough medication - 76% of hospice patients have breakthrough pain on the day before death 7

5. Monitor for opioid accumulation in renal dysfunction - morphine, hydromorphone, and codeine metabolites accumulate; consider fentanyl or buprenorphine instead 1, 5, 2

6. Ensure naloxone availability - discuss with patients and caregivers, prescribe based on overdose risk 1, 3

Evidence Quality Note

The most recent and authoritative guidance comes from the 2025 NCCN Adult Cancer Pain Guidelines 1, which supersedes earlier versions. The FDA fentanyl label 3 provides critical safety parameters. Real-world hospice prescribing data 11, 8 confirms these medications are indeed the most commonly used, validating this approach across diverse patient populations.